A Phase II Study of Axitinib in Patients With Metastatic Renal Cell Cancer Unsuitable for Nephrectomy

NCT01693822 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

65

Enrollment

OTHER

Sponsor class

Conditions

Clear-cell Metastatic Renal Cell Carcinoma

Interventions

DRUG: Axitinib

Sponsor

Institute of Cancer Research, United Kingdom

Collaborators

[object Object]
[object Object]